Compare MGNX & PEBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGNX | PEBK |
|---|---|---|
| Founded | 2000 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 225.6M |
| IPO Year | 2013 | 2012 |
| Metric | MGNX | PEBK |
|---|---|---|
| Price | $2.94 | $39.86 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 600.0K | 27.9K |
| Earning Date | 05-08-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | N/A | ★ 21.48 |
| EPS | N/A | ★ 0.80 |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.19 | N/A |
| P/E Ratio | ★ N/A | $51.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $26.81 |
| 52 Week High | $3.88 | $42.63 |
| Indicator | MGNX | PEBK |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 48.74 |
| Support Level | $1.45 | $38.54 |
| Resistance Level | $3.39 | $40.02 |
| Average True Range (ATR) | 0.20 | 1.11 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 12.32 | 44.12 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.